Hologic, Inc. (NASDAQ:HOLX) – Piper Jaffray Companies decreased their Q1 2020 earnings estimates for shares of Hologic in a research report issued to clients and investors on Wednesday, November 6th. Piper Jaffray Companies analyst W. Quirk now expects that the medical equipment provider will earn $0.62 per share for the quarter, down from their prior forecast of $0.65. Piper Jaffray Companies has a “Overweight” rating and a $59.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Hologic’s Q2 2020 earnings at $0.63 EPS, Q4 2020 earnings at $0.71 EPS, FY2020 earnings at $2.64 EPS, Q1 2021 earnings at $0.67 EPS, Q2 2021 earnings at $0.67 EPS, Q3 2021 earnings at $0.73 EPS, Q4 2021 earnings at $0.77 EPS, FY2021 earnings at $2.84 EPS and FY2022 earnings at $3.09 EPS.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $0.65 EPS for the quarter, hitting the consensus estimate of $0.65. The business had revenue of $865.80 million during the quarter, compared to analysts’ expectations of $846.54 million. Hologic had a negative net margin of 0.89% and a positive return on equity of 27.95%. The firm’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same period last year, the company posted $0.58 earnings per share.
Other equities analysts have also issued research reports about the stock. ValuEngine lowered shares of Hologic from a “hold” rating to a “sell” rating in a research report on Friday, October 25th. Bank of America raised shares of Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the company from $54.00 to $59.00 in a research report on Thursday, September 26th. Argus raised their price objective on shares of Hologic to $62.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. BidaskClub lowered shares of Hologic from a “hold” rating to a “sell” rating in a research report on Thursday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $57.00 price objective (up previously from $52.00) on shares of Hologic in a research report on Thursday, August 1st. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. Hologic has an average rating of “Hold” and a consensus price target of $51.48.
Shares of HOLX opened at $46.56 on Friday. The firm has a market cap of $12.86 billion, a PE ratio of 20.30, a PEG ratio of 2.03 and a beta of 0.76. The firm’s 50 day moving average price is $48.87 and its 200 day moving average price is $48.00. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.11 and a current ratio of 1.57. Hologic has a twelve month low of $37.48 and a twelve month high of $52.19.
Large investors have recently added to or reduced their stakes in the company. CWM LLC raised its position in shares of Hologic by 3,466.7% in the second quarter. CWM LLC now owns 535 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 520 shares during the period. Horan Capital Advisors LLC. bought a new position in shares of Hologic in the third quarter valued at approximately $34,000. CSat Investment Advisory L.P. raised its position in shares of Hologic by 66.9% in the second quarter. CSat Investment Advisory L.P. now owns 831 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 333 shares during the period. SevenBridge Financial Group LLC raised its position in shares of Hologic by 172.0% in the second quarter. SevenBridge Financial Group LLC now owns 1,205 shares of the medical equipment provider’s stock valued at $58,000 after purchasing an additional 762 shares during the period. Finally, North Star Investment Management Corp. bought a new position in shares of Hologic in the third quarter valued at approximately $80,000. 95.33% of the stock is currently owned by institutional investors.
In other news, insider Peter J. Valenti III sold 7,766 shares of Hologic stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $49.14, for a total value of $381,621.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.90% of the stock is currently owned by company insiders.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Article: Special Dividends
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.